On the stock market since 2000, it operates in the world of health and science. It has 11,000 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 11% a year over the last 4 years. Every year shown ended in profit.
The gap is $1.4B. In times of high interest rates, a gap like that can squeeze a company.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Clearly above the class average — a step short of the very top.
Clearly above the class average — a step short of the very top.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
The stock trades below its recent peak — about 13% off the top. A pullback, not a collapse.
Over the last 3 years, sales grew about 12% a year on average.
Over the last 12 months, company executives reported 72 buys and 58 sells. Management buying with its own money is usually read as a good sign.
The company’s market value is 41 times its annual profit. Even a small disappointment could hit the price hard.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 39/100.
On our five-subject report card, ITGR sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: ITGR is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.